Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine risks: real, perceived and unknown.

R T Chen1

  • 1Vaccine Safety and Development Branch, National Immunization Program (MS-E61), Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA. rtc1@cdc.gov

Vaccine
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultracompact and fabrication-tolerant integrated polarization splitter.

Optics letters·2011
Same author

Vacuum-tuned graded-index polymer waveguides on silicon substrates.

Applied optics·2010
Same author

Large fanout optical interconnects using thick holographic gratings and substrate wave propagation.

Applied optics·2010
Same author

Five-channel surface-normal wavelength-division demultiplexer using substrate-guided waves in conjunction with a polymer-based Littrow hologram.

Optics letters·2009
Same author

Wavelength-division multiplexing and demultiplexing on locally sensitized single-mode polymer microstructure waveguides.

Optics letters·2009
Same author

Submicrometer lithography using lensless high-efficiency holographic systems.

Optics letters·2009
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
Same journal

Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.

Vaccine·2026
Same journal

Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.

Vaccine·2026
Same journal

Public health benefits of maternal influenza vaccination among pregnant women and infants <6 months in the United States, 2011-2020.

Vaccine·2026
Same journal

Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial.

Vaccine·2026
See all related articles

As immunizations reduce disease, vaccine safety becomes more prominent. Modernizing vaccine safety infrastructure is crucial for fulfilling the potential of new biotechnology-driven vaccines.

Area of Science:

  • Immunology
  • Public Health
  • Biotechnology

Background:

  • Immunizations have significantly decreased infectious disease incidence.
  • The success of vaccines shifts focus towards vaccine safety.
  • Technological advancements in vaccine development are rapid.

Purpose of the Study:

  • To highlight the increasing importance of vaccine safety.
  • To advocate for infrastructure modernization in vaccine safety.
  • To ensure public confidence in evolving vaccine technologies.

Main Methods:

  • This is a conceptual analysis and perspective piece.
  • It draws parallels with safety infrastructure evolution in the aviation industry.
  • It synthesizes current trends in vaccine development and safety.

Related Experiment Videos

Main Results:

  • Vaccine safety is becoming a more prominent concern as diseases are controlled.
  • A robust safety infrastructure is essential for public trust.
  • Investment in vaccine safety must parallel investment in vaccine development.

Conclusions:

  • The vaccine community must prioritize and evolve its safety infrastructure.
  • Modernized vaccine safety systems are necessary to support new vaccine technologies.
  • Failure to adapt safety infrastructure may hinder the full realization of vaccine advancements.